Bruno Lucidi has been appointed permanent CEO of Karolinska Development.
Bruno Lucidi has previously been founding CEO of Idenix and Chairman of Pharmasset. He has also held senior positions within Bristol-Myers Squibb, Johnson & Johnson and at GlaxoSmithKline. Since September 8, 2014, Bruno Lucidi is CEO of the Karolinska Development’s wholly owned subsidiary KDev Oncology as well as of the portfolio companies Aprea and Akinion. Bruno will keep these positions and will assume his new role as CEO of Karolinska Development.
“I am very pleased to take up this position and look forward to taking Karolinska Development to the next stage in its development”, says CEO Bruno Lucidi. “There are several opportunities to have major positive impact on patients’ lives in our portfolio companies and this represent certainly significant business opportunities. I am definitely convinced that Karolinska Development with its new strategy will be able to unlock these values”.
Lucidi will assume his new position and take over from acting CEO Klaus Wilgenbus with immediate effect on October 15, 2014.
“We are happy to welcome Bruno Lucidi as permanent CEO”, says Karolinska Development’s Chairman Bo Jesper Hansen. “As communicated on September 30, 2014, we need a new strategy and a new leadership to realize the true potential of Karolinska Development and its portfolio companies. We are convinced that Bruno has the right skills and experiences to lead the company during this important phase where a more effective and compelling strategy for the future needs to be executed”.
